Patents by Inventor David Witty

David Witty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230181749
    Abstract: The present invention relates to a Bicycle toxin conjugate BT8009, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof. In one embodiment, the pharmaceutical composition comprises BT8009, histidine, sucrose and Polysorbate 20. In another embodiment, the pharmaceutical composition is for use in treating an advanced solid tumor malignancy associated with Nectin-4-expression in a patient, preferably in combination with Nivolumab.
    Type: Application
    Filed: May 20, 2021
    Publication date: June 15, 2023
    Inventors: Amy Katherine DICKSON, Darren LIMB, Lisa MAHNKE, Michael RIGBY, Terrence Allen WEST, David WITTY
  • Patent number: 11396530
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: July 26, 2022
    Assignee: BICYCLETX LIMITED
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Publication number: 20220169653
    Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.
    Type: Application
    Filed: September 3, 2021
    Publication date: June 2, 2022
    Inventors: David AMANTINI, Milan MESIC, Gordon SAXTY, Tanja POLJAK, Ines VUJASINOVIC, Dinko ZIHER, David WITTY, Karl Richard GIBSON
  • Patent number: 11136325
    Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: October 5, 2021
    Assignee: GALAPAGOS NV
    Inventors: David Amantini, Milan Mesic, Gordon Saxty, Tanja Poljak, Ines Vujasinovic, Dinko Ziher, David Witty, Karl Richard Gibson
  • Publication number: 20210147484
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 28, 2020
    Publication date: May 20, 2021
    Inventors: Paul BESWICK, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Patent number: 10919937
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: February 16, 2021
    Assignee: BicycleTx Limited
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Publication number: 20200165259
    Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.
    Type: Application
    Filed: July 12, 2018
    Publication date: May 28, 2020
    Inventors: David AMANTINI, Milan MESIC, Gordon SAXTY, Tanja POLJAK, Ines VUJASINOVIC, Dinko ZIHER, David WITTY, Karl Richard GIBSON
  • Publication number: 20200131228
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 23, 2019
    Publication date: April 30, 2020
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Patent number: 10421716
    Abstract: The invention relates to a novel process for preparing ?-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide, and to novel intermediates for use in said process along with processes for preparing said intermediates.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: September 24, 2019
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: David MacPherson, David Witty, Gerard Giblin, Michael Williams, Donald Walker, William Kiesman, Tamera Mack
  • Publication number: 20170369437
    Abstract: The invention relates to a novel process for preparing ?-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide, and to novel intermediates for use in said process along with processes for preparing said intermediates.
    Type: Application
    Filed: December 23, 2015
    Publication date: December 28, 2017
    Inventors: David MacPherson, David WITTY, Gerard GIBLIN, Michael WILLIAMS, Donald WALKER, William KIESMAN, Tamera MACK
  • Publication number: 20070249603
    Abstract: The present invention relates to novel quinoline derivatives such as compounds of the formula (I) which have antagonist potency for the 5-HT6 receptor: and the use of such compounds or pharmaceutical compositions thereof in the treatment of CNS and other disorders.
    Type: Application
    Filed: May 19, 2005
    Publication date: October 25, 2007
    Inventors: Christopher Johnson, Geoffrey Stemp, Mervyn Thompson, David Witty
  • Publication number: 20070191345
    Abstract: The present invention relates to novel quinoline derivatives such as compounds of the formula (I): and the use of such compounds or pharmaceutical compositions thereof in the treatment of CNS and other disorders.
    Type: Application
    Filed: March 24, 2005
    Publication date: August 16, 2007
    Applicant: GLAXO GROUP LIMITED
    Inventors: Mahmood Ahmed, Christopher Johnson, Neil Miller, Giancarlo Trani, David Witty
  • Publication number: 20070117820
    Abstract: Compounds of formula (I): or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein: P, P?, R1, R2, n, p, q, r, and s are as defined in the specification, processes for preparing such compounds, pharmaceutical compositions comprising such compounds and their use in therapy.
    Type: Application
    Filed: March 5, 2004
    Publication date: May 24, 2007
    Applicant: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Stephen Moss, Harshad Rami, Mervyn Thompson, David Witty
  • Publication number: 20070027139
    Abstract: This invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
    Type: Application
    Filed: September 23, 2004
    Publication date: February 1, 2007
    Inventors: Christopher Johnson, Stephen Moss, David Witty
  • Publication number: 20060287334
    Abstract: This invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
    Type: Application
    Filed: September 9, 2004
    Publication date: December 21, 2006
    Inventors: Christopher Johnson, David Witty
  • Publication number: 20060287321
    Abstract: The invention thus provides compounds of formula (I) a salt, or solvate thereof.
    Type: Application
    Filed: August 23, 2006
    Publication date: December 21, 2006
    Applicant: SMITHKLINE BEECHAM P.L.C.
    Inventors: Sula Armstrong, Dieter Hamprecht, Martin Jones, David Witty, Kamal Al-Baraznji, Mohammad Tadayyon
  • Publication number: 20060276447
    Abstract: Compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein P, P?, W, R1, R2, n, p, q, r, s and t are as defined in the specification, processes for preparing such compounds, pharmaceutical compositions comprising such compounds and their use in therapy.
    Type: Application
    Filed: March 4, 2004
    Publication date: December 7, 2006
    Inventors: Stephen Fell, Harshad Rami, Mervyn Thompson, David Witty
  • Publication number: 20050222124
    Abstract: The invention provides compounds of formula (I) wherein A and B represent the groups —(CH2)m- and —(CH2)n-respectively; R1 represents hydrogen or C1-6alkyl; R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C3-7cycloalkylC1-6alkoxy, —(CH2)pC3-6cycloalkyl, —(CH2)pC3-6cycloalkyloxy, —COC1-6alkyl, —SO2C1-6alkyl, —SOC1-6alkyl, —S—C1-6alkyl, C1-6alkylsulfonyloxy, C1-6alkylsulfonylC1-6alkyl, —CO2C1-6alkyl, —CO2NR7R8, —SO2NR7R8, C1-6alkylsulfonamido, C1-6alkylsulfonamidoC1-6alkyl, —(CH2)pNR7R8, C1-6alkylamidoC1-6alkyl, —(CH2)pNR7COR8, arylsulfonyl, arylsulfonyloxy, arylsulfonylC1-6alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC1-6alkyl, arylcarboxamidoC1-6alkyl, aroyl, aroylC1-6alkyl, arylC1-6alkanoyl, —SO2NR7R8, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclyl, or a group CONR7R8 or SO2NR7R8 wherein R7 and R8 together may be fused to form a 5-
    Type: Application
    Filed: February 13, 2003
    Publication date: October 6, 2005
    Inventors: Steven Bromidge, David Cooper, Ian Forbes, Andrew Gribble, Christopher Johnson, Andrew Plightfoot, Stephen Moss, Andrew Payne, Shahzad Rahman, David Witty
  • Publication number: 20050176759
    Abstract: Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Application
    Filed: December 20, 2002
    Publication date: August 11, 2005
    Inventors: Mahmood Ahmed, Steven Bromidge, Ian Forbes, Andrew Gribble, Christopher Johnson, Francis King, Andrew Lightfoot, Gregor Macdonald, Stephen Moss, Mervyn Thompson, David Witty
  • Publication number: 20050124626
    Abstract: The present invention relates to novel quinoline and aza indole compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
    Type: Application
    Filed: March 25, 2003
    Publication date: June 9, 2005
    Inventors: Christopher Johnson, Gregor Macdonald, Darren Mitchell, Stephen Moss, Mervyn Thompson, David Witty